Company Directory / research
PrivateFor profitresearchBasel, Switzerland
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
- Founded
- 2017 9 years ago
- Staff
- 51-100 band, as listed
- Followers
- - on LinkedIn
- Funding
- $232M as listed, currency not stated
Set against six million companies
Size
51-100 people: larger than 75% of companies with a size listed
Age
9 years old.
Reach
Website ranked #2,874,247 in the world for traffic, about 6k visits a month.
What it does
BiotechnologyLife ScienceMedicalTherapeutics
Funding, as listed
$232M currency not stated
- Rounds3
- LatestSeries c, Jun 2024
- Investors11, 3 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Bright Peak Therapeutics, field by field. Contact details are held but never shown.
The company
- Name
- Bright Peak Therapeutics
- Type
- For profit
- Status
- Private
- Founded
- 2017
- Founders
- Jeffrey Bode, Vijaya Pattabiraman
- Industry
- research
- Categories
- Biotechnology, Life Science, Medical, Therapeutics
Where
- City
- Basel
- Country
- Switzerland
- Markets
- Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 51-100
- Web traffic rank
- #2,874,247
- Monthly web visits
- 5,712
Funding, as listed
- Total
- 232,000,000 (currency not stated)
- Rounds
- 3
- Latest round
- Series c
- Latest round date
- Jun 2024
- Investors
- 11
- Lead investors
- 3
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Bright Peak Therapeutics may be growing as evidenced by their recent presentation of new data at the 2024 American Association for Cancer Research Annual Meeting, which suggests ongoing research and development activities. The company's involvement in the field of immunotherapies for cancer and autoimmune diseases aligns with the industry's focus on enhancing cell therapies, as indicated by the growing interest in the IL-18 field. Furthermore, the mention of techbio soonicorns poised to cross the $1 billion threshold reflects a positive trend in the biotech industry, which may indirectly suggest a favorable environment for companies like Bright Peak Therapeutics.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in Switzerland.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 36,795 companies in Switzerland and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.